Interestingly, elevated levels of ephrin-B2 have been reported in the remodeled blood vessels of tumors that recur after anti-angiogenic treatments [65] and the soluble extracellular domain of EphB4 has been shown to disrupt tumor endothelial cell coverage by mural cells in vivo[30], [31]. This evidence concerns the gene EPHB4 and neoplasm.